Blueblood Ventures sells SJM shares for Rs 5.33 crore after purchase

Blueblood Ventures Limited sold 62,500 shares of SJM Investments (Delhi) Private Limited for Rs 5.33 crore under a 28 October 2026 agreement, after buying the same quantity at Rs 825 a share. Blueblood Ventures disclosed the sale, a Rs 4.47 crore loan agreement and a Rs 17.16 crore debt assignment at its 13 November 2026 board meeting.

What SJM Investments shares did Blueblood Ventures buy?

Blueblood Ventures bought 62,500 equity shares of SJM Investments (Delhi) Private Limited at Rs 825 per share in a transaction the filing lists under related-party transactions. The board took note of the purchase in its outcome filed on 13 November 2026, but the disclosure does not state the date on which the company acquired the shares. The stated share count and rate imply purchase consideration of Rs 5.16 crore.

The shares were acquired from four named sellers, with Rohit Bohra accounting for the largest disclosed allocation of 25,525 shares. Beta Stock Brokers was identified as the proprietorship of Suresh Bohra, while the other sellers were Babsons HUF, Babita Bohra and Rohit Bohra. The seller allocations total the disclosed 62,500 shares.

The filing gives one common rate of Rs 825 per share but does not provide a valuation method, the consideration paid to each seller, or SJM Investments' share capital. It also does not state what percentage of SJM Investments was represented by 62,500 shares. The disclosed fact is limited to a purchase from four sellers at the stated rate.

How did Blueblood Ventures' sale compare with its purchase?

Blueblood Ventures sold the same 62,500 SJM Investments shares to Dr. Bilha Theresa K. J. for Rs 5.33 crore under a share transfer agreement dated 28 October 2026. The sale consideration was Rs 17.46 lakh above the Rs 5.16 crore amount implied by the earlier disclosed purchase rate and number of shares. Blueblood Ventures did not state that this difference was a realised gain.

The comparison is arithmetic based on the company’s disclosed purchase price and its stated sale consideration. The filing does not disclose transaction costs, taxes, settlement status, accounting treatment or the reason for the difference between the two amounts. It likewise does not state whether the underlying purchase was completed before the 28 October 2026 sale agreement.

Blueblood Ventures' board took note of the share sale at the meeting held on 13 November 2026, which started at 10:00 p.m. and ended at 11:30 p.m. The filing identifies Dr. Bilha Theresa K. J. as the buyer but does not describe her relationship with SJM Investments or set out conditions attached to the transfer of the 62,500 shares.

What was the loan agreement with Dr. Bilha Theresa K. J.?

Blueblood Ventures executed a loan agreement with Dr. Bilha Theresa K. J. for Rs 4.47 crore on 28 October 2026. That is Rs 86.21 lakh below the Rs 5.33 crore consideration stated for the SJM Investments share sale, and both agreements carry the same date. The board took note of both arrangements on 13 November 2026.

The filing does not identify whether Blueblood Ventures was the lender or borrower under the Rs 4.47 crore agreement. It also gives no interest rate, duration, repayment schedule, security, default terms or use of funds. Accordingly, the disclosed amount cannot establish whether the loan financed, settled or was otherwise linked to the share transfer.

Blueblood Ventures recorded the SJM Investments purchase under the heading of related-party transactions and said the transactions were disclosed under Regulations 23 and 30 of the Securities and Exchange Board of India’s Listing Obligations and Disclosure Requirements Regulations, 2015. The notice does not separately classify the loan as a related-party transaction, despite naming the same counterparty as the share buyer.

What debt did Blueblood Ventures assign to the share buyer?

Blueblood Ventures assigned debt totalling Rs 17.16 crore in favour of Dr. Bilha Theresa K. J. The amount exceeded both the Rs 5.33 crore share-sale consideration and the Rs 4.47 crore loan amount disclosed in the same 13 November 2026 board outcome. The company said the assigned debt related to three named individuals.

The largest stated component was Rs 10.73 crore relating to Anuranjan Jha. The filing listed Rs 4.15 crore relating to Pradeep Kumar Jha and Rs 2.29 crore relating to Amit Kumar Kushwaha. Blueblood Ventures presented the three amounts as an aggregate debt assignment of Rs 17.16 crore in favour of Dr. Bilha Theresa K. J.

The announcement does not state the date of the debt-assignment agreement, consideration paid for the assignment, original nature of the debts, maturity dates or security. It also does not say whether the assignee has recourse against Blueblood Ventures. The disclosed connection across the sale, loan and assignment is that Dr. Bilha Theresa K. J. was the share buyer, loan counterparty and beneficiary of the debt assignment.

When did Blueblood Ventures disclose the transactions and financial results?

Blueblood Ventures disclosed the transactions in the outcome of its board meeting dated 13 November 2026, alongside approval of standalone unaudited results for the half year ended 30 September 2026. The company said the Audit Committee reviewed and recommended the results before board approval. KRA & Associates issued its review report on 13 November 2026.

The auditor highlighted old debit balances of long-term loans and advances of Rs 61.89 crore, which management had considered good while being hopeful of recovery or adjustment. The same report referred to zero optional convertible debentures valued at Rs 7.56 crore as at 30 September 2025. Of 756 debentures, 509 were in the demat account and 247 had been wrongly transferred to one party.

KRA & Associates said its conclusion was not modified in respect of the matters it highlighted. The auditor also referred to a service-tax matter of Rs 27.04 lakh related to financial year 2017-18, for which the company filed an SVLDR-1 form under the Sabka Vishwas (Legacy Dispute Resolution) Scheme on 15 January 2020. These audit observations were disclosed separately from the 28 October 2026 share, loan and debt arrangements.

Conclusion

Blueblood Ventures disclosed a sequence of transactions centred on 62,500 SJM Investments shares: a purchase at Rs 825 per share, followed by a Rs 5.33 crore sale to Dr. Bilha Theresa K. J. The filing also records a Rs 4.47 crore loan agreement with the same counterparty and a separate Rs 17.16 crore debt assignment in her favour, without setting out contractual links between them.

The next disclosed matters to watch are management's process to return 247 wrongly transferred debentures to the demat account and its hoped-for recovery or adjustment of Rs 61.89 crore in old long-term loan and advance balances. The filing does not disclose completion, repayment, settlement or assignment-consideration details for the agreements dated 28 October 2026.